Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

ClinicalTrials.gov ID: NCT02283762

Public ClinicalTrials.gov record NCT02283762. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Study identification

NCT ID
NCT02283762
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bayer
Industry
Enrollment
121 participants

Conditions and interventions

Interventions

  • Riociguat (Adempas, BAY63-2521) Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 14, 2015
Primary completion
Dec 14, 2017
Completion
Mar 27, 2019
Last update posted
Feb 4, 2020

2015 – 2019

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Mayo Clinic - Scottsdale Scottsdale Arizona 85259-5404
UCLA David Geffen School of Medicine Los Angeles California 90095-1670
Stanford University School of Medicine Palo Alto California 94304
University of Connecticut Health Center Farmington Connecticut 06030
Georgetown University Medical Center Washington D.C. District of Columbia 20007
University of Michigan Health System Ann Arbor Michigan 48109
Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey 08901
Medical University of South Carolina Medical Center Charleston South Carolina 29425
Memorial Hermann-Texas Medical Center Houston Texas 77030
University of Utah Health Care Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02283762, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 4, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02283762 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →